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of these patients, the overall prognosis was poor, with a 
cumulative 5 year survival rate of just 46.2 %.
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Introduction
The association of cancer with CD was not known until 
many years after the classic description of “regional enteri-
tis” in 1932; thus, information about cancer epidemiology 
in those patients is limited. Recent studies have found that 
CD is associated with an increased risk of malignancy [1, 
2]. Three types of gastrointestinal carcinomas have been 
shown to occur more frequently in patients with CD than 
in the general population: small bowel cancer, colorectal 
cancer (CRC), and carcinoma arising from a perianal fistula 
[2–6], with the presence of anal carcinoma in these patients 
clearly associated with a long-standing perianal fistula. It is 
important to note that malignancy can arise in association 
with CD-related perianal disease. Thus, attending physi-
cians should have a high level of suspicion towards cancer 




Between September, 1974 and December, 2014, 1096 
patients underwent surgery for CD at our institution. Can-
cer was confirmed in specimens resected from 34 of these 
patients, who were the subjects of this study.
Abstract 
Purpose We examined the clinicopathological character-
istics and prognosis of patients with cancer associated with 
Crohn’s disease (CD).
Methods The subjects of this study were patients with 
cancer confirmed in a resected specimen of bowel, who 
were treated at our institution between September, 1974 
and December, 2014.
Results We analyzed 34 patients (26 men, 8 women, 
median age at cancer diagnosis 43.5 years, duration of ill-
ness 18 years) and found that the number of those with CD 
complicated with cancer began to drastically increase after 
2005. The site of onset of cancer was in an anorectal lesion 
in 24 (70.6 %) patients. In 17 (50 %) patients, the cancer 
was diagnosed before surgery; in 3 patients (8.8 %), it was 
based on pathological findings during surgery; and in 14 
patients (41.2 %), it was based on postoperative pathologi-
cal findings. Mucinous carcinoma was the dominant histo-
logical type, seen in 15 patients (44.1 %), while the special 
type of signet-ring cell carcinoma was found in 4 patients. 
The cumulative overall 5 year survival rate was 46.2 %.
Conclusion In this group of Japanese CD patients, an 
anorectal lesion was the most frequent site of origin of can-
cer. As cancer was diagnosed preoperatively in only 50 % 
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Methods
We analyzed retrospectively the clinicopathological charac-
teristics and prognoses of patients with cancer associated 
with CD, who were treated at our institution. The cancers 
were staged according to the 7th UICC TNM staging sys-
tem based on results of the final pathological examination, 
and follow-up examinations were performed until the time 
of death or closing date of the study (March 31, 2015).
Statistical analysis
All statistical analyses were performed using JMP version 
11 (SAS Institute Inc., Cary, NC). Fisher’s exact test was 
used for categorical data. Otherwise, patients were divided 
into two groups based on the median value of their age at 
onset and at their first operation (24- and 37-years-old, 
respectively). Multivariate analysis findings are expressed 
as odds ratios and 95 % confidence interval values. A p 
value of <0.05 was considered significant. Cumulative 
5 year survival was analyzed using the Kaplan–Meier 
method and the log-rank test.
Results
Changes in the number of cancer cases
In 2000, we encountered our first case of cancer associated 
CD and from 2005, the number of cases of CD complicated 
by cancer increased dramatically. By December, 2014, we 
had treated 34 such patients in our department (Fig. 1).
Clinical characteristics
There were 26 men and 8 women, with a median age at 
cancer diagnosis of 43.5 years and a duration of illness of 
18 years (Table 1).
Location of CD‑related cancer
Table 2 shows the sites where cancer arose in our patients 
with CD. The lesions were most commonly found in the 
anal fistula (n = 9, 26.5 %), followed by the anal canal 
(n = 8, 23.5 %), and rectum (n = 7, 20.6 %). CD-related 
cancer was discovered in anorectal lesions in 24 (70.6 %) 
of our patients.
Time and method of diagnosis
Table 3 shows the time and methods of diagnosis. In 17 
patients (50 %), the diagnosis was made before surgery, 
whereas in 3 patients (8.8 %) it was based on pathological 










Fig. 1  Changes in the number of cases of colorectal cancer among patients with Crohn’s disease (CD). The number of CD patients with cancer 
increased dramatically after 2005
Table 1  Clinical characteristics
Sex (male/female) 26/8
Age at onset in years (range) 24.0 (11–60)
Age at cancer diagnosis in years 
(range)
43.5 (27–73)
Duration of disease in years  
(range)
18 (6–37)
Extent of disease at first operation Ilitis: 4, colitis: 2, ileocolitis: 28
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Histology
Mucinous carcinoma was the dominant type of cancer, 
diagnosed in 15 patients (44.1 %), while special type sig-
net-ring cell carcinoma was diagnosed in 4 (Table 4).
Progression, stage, and prognosis
Table 5 shows the progression, stage, and prognosis on 
the closing date of the study. The mean period until death 
was 14.5 months (range 3–109 months). For the patients 
who survived, the mean period from operation to the clos-
ing date of the study (March 31, 2015) was 35.3 months 
(10–129 months). The stage was analyzed after excluding 
special cases such as fistula cancer. Stage II was the most 
common, found in 16 patients, 8 of whom were recurrence-
free, 2 of whom had local recurrence, and 1 of whom had 
distal metastasis. Five patients with recurrence died of the 
disease.
Preoperative treatment and cancer remaining 
after surgery (Table 6)
Eight of the 24 CD patients with cancer discovered in an 
anorectal lesion underwent chemoradiotherapy. Twenty 
(58.8 %) of the 34 patients in the total cohort underwent 
microscopic curative resection and 14 (41.2 %) underwent 
macroscopic or microscopic non-curative resection, or the 
remaining cancer could not be detected.
Cumulative 5 year survival rate
Follow-up examinations were performed until either death 
or the closing date of the study (March 31, 2015). The 
cumulative overall 5 year survival rate was 46.2 % (Fig. 2).
Pathological types and cumulative 5 year survival rate
The cumulative 5 year survival rate for the patients with 
moderately differentiated or well differentiated adenocarci-
noma was 75.0 %, whereas that for the patients with other 
histological types (poorly differentiated adenocarcinoma, 
mucinous carcinoma, signet-ring cell carcinoma, or squa-
mous cell carcinoma) was significantly worse at 30.5 % 
(p = 0.02; Fig. 3).
Table 2  Location of cancer in CD patients (n = 34)
Location Patients (%)
Fistula 4 (11.8)
 Entero-enteric 3 (8.8)
 Entero-cutaneous 1 (2.9)
Intestine 30 (88.2)
 Ileum 2 (5.9)
 Cecum 2 (5.9)
 Descending colon 1 (2.9)
 Sigmoid colon 1 (2.9)
 Rectum 7 (20.6)
 Anal fistula 9 (26.5)
 Anal canal 8 (23.5)
Table 3  Time and method of diagnosis
Time Method No. of cases
Preoperative Endoscopy 12
Curettage of fistula 3
Direct tumor biopsy 2
Intraoperative Pathological examination 3
Postoperative Pathological examination 14
Table 4  Histology
Location Histology No. of cases




Ileum Well differentiated 1
Poorly differentiated 1
Colon Well differentiated 3
Mucinous 1




Table 5  Progression stage and prognosis
Stage Prognosis No. of cases
0, I (6) No recurrence 5
Local recurrence 1




IIIa (2) Death 2
IIIb (4) No recurrence 2
Death 2
IIIc (l) Death 1
IV (1) Death 1
Classification not possible (4) Death 4
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Risk factors for cancer development in CD patients
Table 7 details the results of univariate and multivariate 
analyses. Univariate analysis showed a significant differ-
ence in the site of disease at the first operation and age at 
the first operation. The presence of an anal lesion at the first 
operation and smoking status were not shown to be signifi-
cant factors. These results were confirmed by multivariate 
analysis, which revealed extent of disease and age at the 
first operation as significant factors.
Discussion
Colorectal cancer (CRC) in a patient with CD was first 
described in 1948 [7]. Recent studies have demonstrated 
that CD carries an increased risk of malignancy [1, 2], 
although it should be noted that there are regional differ-
ences in regard to the location of cancer in those patients. 
Stahl et al. reported that only 17 % (n = 4) of cancerous 
lesions in their CD patients were located in the rectum, 
which was a much lower incidence than for sporadic can-
cer (38 %). On the other hand, 59 % (n = 14) were located 
in the ascending or transverse colon, which was signifi-
cantly higher than for sporadic cancer (28 %) [8]. More-
over, Kersting et al. reviewed previous studies and found 
that 39–50 % of CD-associated tumors were located in the 
rectum [5, 9]. They noted that the majority of CD-associ-
ated tumors were located in an intestinal segment that was 
easily accessible for an endoscopic examination. On the 
other hand, Mizushima et al. reported that 34 of 44 CRCs 
(77.3 %) in Japanese patients with CD arose in the sigmoid 
colon, rectum, or anal canal/fistula [10]. According to some 
reports from Western countries, patients with CD showed 
an increased risk of colon cancer but not rectal cancer [11]. 
Thus, there may be genetic and environmental factors asso-
ciated with the development of CRC in patients with CD.
Some studies have investigated the risk of cancer 
development in CD patients. Scaringi et al. reported that 
Table 6  Preoperative treatment 
and cancer remaining after 
surgery
CRT chemo-radio therapy, RX remaining cancer could not be determined, R0 no cancerous remnant, R1 
resected surface of remnant histologically positive, R2 large portion of cancerous tissue remained
Location No. of cases Preoperative CRT Level of remaining cancer
RX R0 R1 R2
Fistula 4 0 2 2
 Entero-enteric 3 0 1 2
 Entero-cutaneous 1 0 1
Intestine 30 2 18 7 3
 Ileum 3 0 2 1
 Colon 3 0 3
 Rectum 7 2 5 2
 Anal fistula 9 4 2 4 2 1
 Anal canal 8 2 4 3 1
Fig. 2  Cumulative 5-year survival rate. The cumulative 5 year sur-
vival rate was 46.4 %
Fig. 3  Pathological types and cumulative 5 year survival rate
39Surg Today (2017) 47:35–41 
1 3
CD patients who require surgery are at higher risk of the 
development of colorectal cancer, particularly those whose 
disease duration is >10 years, have distal localization, are 
<40-years-old at diagnosis, and have penetrating disease 
[12]. In the present study, the site of disease (colon involve-
ment) at the first operation and age at the first operation 
were associated with an increased risk of the development 
of cancer in Japanese CD patients.
Recent studies have indicated the potential of FDG-PET 
to assess CD activity [13–15], although to our knowledge, 
there is no report on its potential to assess CD-associated 
malignant tumors. We performed FDG-PET in four of our 
patients prior to surgery and the results were positive in 
two patients and negative in two [16]. Based on our lim-
ited experience, FDG-PET does not have a high accuracy 
rate, possibly because of the high incidence of mucinous 
cell type carcinoma among CD-associated cancers. Whit-
eford et al. also reported that the sensitivity of FDG-PET 
for detecting mucinous carcinoma was lower than that for 
non-mucinous cancer [17]. We think that magnetic reso-
nance imaging (MRI) is more effective than FDG-PET for 
CD patients with anorectal carcinoma. For anorectal can-
cer, pelvic MRI is the best method for examining cancer 
localization and invasion, as well as its positional relation-
ship with surrounding organs. An anal fistula carcinoma 
associated with mucinous cancer frequently shows mucus 
retention; thus, multilocular cyst-like findings are often 
observed on T2-weighted MRI images. Figure 4 shows 
representative T2-weighted MRI findings of a CD patient 
with mucinous cancer case (multilocular cyst indicated by 
arrow).
No conclusions can be drawn from the present study 
about the efficacy of adjuvant chemo-radiation treatment 
for CD patients with a fistula-associated anal adenocarci-
noma because of the small number of subjects analyzed 
and the retrospective nature of the study. Furthermore, it is 
difficult to evaluate tumor regression grade in patients with 
CD-associated lower rectal carcinoma, as most colonic 
carcinomas in CD patients are of the mucinous cell type. 
Sengul et al. compared outcomes following preoperative 
chemo-radiation treatment in 16 patients with mucinous 
rectal cancer and 55 with non-mucinous rectal cancer 
[18]. Those with mucinous tumors had significantly more 
advanced T stage after chemoradiotherapy, whereas only 
18 % of those patients had a shift toward earlier T and N 
stages, compared with 74 % of patients with non-mucinous 
Table 7  Univariate and 
multivariate analyses of risk 
factors for cancer associated CD
Factors Univariable analysis Multivariable analysis
Cancer OR 95 % CI P OR 95 % CI P
Age at onset
 ≥24 years 17 (50.0) 1.24 0.62–2.46 0.600
 <24 years 17 (50.0)
Sex
 Man 26 (76.5) 0.81 0.36–1.81 0.699
 Woman 8 (23.5)
Age at first operation
 ≥37 years 17 (50.0) 3.00 1.51–5.97 0.0022 3.38 1.68–6.79 0.0008
 <37 years 17 (50.0)
Site of disease
 Ilitis 5 (14.3) 3.45 1.20–9.88 0.0134 3.99 1.54–6.79 0.0027
 Ileo-colitis + colitis 29 (85.3)
Anal lesion at  initial surgery
 Present 23 (67.6) 1.59 0.76–3.29 0.223
 Absent 11 (32.4)
Type of disease
 Perforating 18 (52.9) 1.52 0.77–3.02 0 221
 Non-perforating 16 (47.1)
Active smoking
 Yes 7 (20.6) 0.63 0.27–1.47 0.338
 No 27 (79.4)
Alcohol habit
 Yes 4 (11.8) 0.79 0.27–2.29 0.179
 No 30 (88.2)
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cancer. On the other hand, Wolfgang et al. reported good 
results, with combined judging of their results, for all seven 
of their patients for whom this treatment achieved a com-
plete response. They concluded that neo-adjuvant chemo-
radiotherapy may play an important role in the treatment 
of locally advanced disease [19]. In the present study, eight 
patients were treated with neo-adjuvant chemo-radiation, 
but by the end of the study period, six of these patients had 
died, one distant metastasis, and one had local recurrence. 
Based on these results, we do not consider that neo-adju-
vant chemoradiotherapy is effective for patients with CD-
associated anorectal cancer.
Although the outcome of patients with a CD-associated 
cancer is the same as that of those with sporadic cancer at 
a corresponding stage, the prognosis for the former is often 
worse due to the advanced stage at time of diagnosis, as 
there are no formal guidelines for the screening and sur-
veillance of cancer associated with CD. We usually per-
form a surveillance colonoscopy examination for ulcera-
tive colitis (UC) patients, but colonoscopy is not possible 
in CD patients because of the associated anorectal stenosis 
or pain.
We previously reported that the 5 year survival rate of 
patients with UC-associated colorectal cancer was 89 % 
[20], which was improved from earlier reports, probably 
because surveillance colonoscopy is effective for detect-
ing colorectal cancer at an early stage. On the other hand, 
we do not know of any report on the 5 year survival rate 
of patients with CD-associated intestinal cancer. In the 
present study, the cumulative 5 year survival rate for CD-
associated cancer was only 46.2 %, which is worse than 
that for UC patients. Lack of suspicion in the early stages, 
and inadequate physical or colonoscopy examinations due 
to exacerbation of perianal symptoms may delay diagnosis. 
Laurent et al. noted that a high degree of suspicion for car-
cinoma is needed during rectal examination of CD patients 
and recommended biopsy, curettage, or brushing of the fis-
tulous tract [21]. We agree that repeated biopsy procedures 
are necessary and should be performed when there is exac-
erbation of local symptoms and signs, such as increased 
pain with discharge or bleeding, or if the attending physi-
cian has any concerns.
Conclusion
Since 2005, the incidence of CD-associated cancer has 
been increasing in our Japanese patients, with an anorec-
tal lesion the most frequent site of occurrence. An accu-
rate preoperative diagnosis was made in only 50 % of the 
patients in this series. Thus, patient prognosis was poor, 
with a cumulative 5 year survival rate of only 46.2 %.
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